Eli Lilly and Company’s Post

Purdue University is proud to partner with Eli Lilly and Company and Merck & Co. Inc. to launch the Young Institute's Pharmaceutical Manufacturing Consortium. This collaboration will make a global impact in solving complex problems in the #pharmaceutical and #biopharmaceutical manufacturing ecosystem as consortium partners revolutionize pharmaceutical manufacturing with a focus on sterile injectables and innovative aseptic manufacturing #technology to ensure quality, safety and compliance. This partnership also presents another dimension of #Purdue’s One Health initiative. https://lnkd.in/gXjTiQe9

This new collaboration between Purdue University, Eli Lilly and Company, and Merck will revolutionize pharmaceutical manufacturing with a focus on sterile injectables and innovative aseptic manufacturing technology to ensure quality, safety and compliance. https://lnkd.in/gAvXutxJ

What’s the future of pharmaceutical packaging? Take a listen to this EPR podcast to find out more.

WEBINAR: Continuous Lyophilization of Pharmaceutical Products in Unit Doses Fill out the form to download your copy: https://lnkd.in/dxkt_Sx #lyophilization #pharma #pharmaceutical #freezedrying #drugdevelopment #RandD #drugtesting #drugsafety #drugmanufacturing

Purdue University, in collaboration with Eli Lilly and Company and Merck Group announced the launch of the Young Institute Pharmaceutical Manufacturing Consortium, a collaborative effort to pioneer advances in making medicines. Karen Plaut Arup Roy #healthcare #PharmaIndustrialIndia

The global pharmaceutical market is 1475 billion USD in 2022 growing at a CAGR of 5% during the next six years. In comparison the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U. S. dollars in 2022. #PharmaceuticalRobotics #LabAutomation #DrugDiscovery #ResearchInnovation #GlobalMarket #LabEfficiency #RoboticTechnology #PharmaResearch #ScientificAdvancement #HealthcareInnovation

Big Pharma is making a big shift toward U.S.-based manufacturing! With billion-dollar investments by Amgen, Eli Lilly, and AstraZeneca, the pharmaceutical industry is building a more resilient supply chain, reducing reliance on overseas production, and bringing manufacturing closer to patients. But why this push now? Read the news here: 🔗https://ow.ly/OJey50U6Sth #Pharmaceuticals #Manufacturing #SupplyChain #MTmagazine

"Continuus production directly benefits consumers by addressing issues like drug shortages and high prices. By making drugs more readily available and keeping costs down, we are addressing major pain points in the pharmaceutical supply chain." Click below to read the full interview with our CEO Salvatore Mascia

The U.S. is ripe with opportunity for a thriving, domestic biomanufacturing industry and today’s news of our project agreement with the BioMaP-Consortium | Biopharmaceutical Manufacturing Preparedness Consortium is a big step toward unlocking that potential. Onshoring these critical pharmaceutical supply chains to the U.S. is imperative and biomanufacturing is the leading solution for achieving this goal.   Having the support of the BioMaP-Consortium and new investors IQT (In-Q-Tel) and Echo will be critical in our efforts to transform pharma supply chains and onshore production of some of our most vital essential medicines.

'Ensuring packaging integrity of frozen biopharmaceutical products'. Freezing biological drug products can expose vials to significant mechanical stress, risking packaging integrity. A recent study, featured in European Pharmaceutical Review investigates how different vial qualities perform under the thermally induced stresses of frozen drug product preparation and storage. These insights help pharmaceutical professionals make informed decisions when selecting primary packaging for frozen biological products to ensure product safety and reliability. 👉 Read the full article here: https://hubs.li/Q032Yqxt0